Crinetics Pharmaceuticals Inc logo

CRNX - Crinetics Pharmaceuticals Inc Share Price

$17.06 -0.6  -3.4%

Last Trade - 7:32pm

Mid Cap
Market Cap £465.2m
Enterprise Value £374.7m
Revenue £719k
Position in Universe 2752nd / 6345
Unlock CRNX Revenue
Relative Strength (%)
1m +11.1%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -33.8%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2014 2015 2016 2017 2018 2019 2020E 2021E CAGR / Avg
0.000 0.000 0.59 2.05 2.43 1.19 0.036 +26.5%
Balance Sheet
FINANCIAL BRIEF: : For the three months ended 31 March 2020, Crinetics Pharmaceuticals Inc revenues decreased 81% to $71K. Net loss increased 93% to $17.4M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Research and development - Balancing val increase of 90% to $12.8M (expense), Stock-based Compensation in SGA increase from $489K to $1.1M (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History


CRNX Revenue Unlock CRNX Revenue

Net Income

CRNX Net Income Unlock CRNX Revenue

Normalised EPS

CRNX Normalised EPS Unlock CRNX Revenue

PE Ratio Range

CRNX PE Ratio Range Unlock CRNX Revenue

Dividend Yield Range

CRNX Dividend Yield Range Unlock CRNX Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
CRNX EPS Forecasts Unlock CRNX Revenue
Profile Summary

Crinetics Pharmaceuticals, Inc. is a clinical stage pharmaceutical company. The Company is focused on the discovery and development of drugs to treat specialty endocrine diseases and endocrine-related tumors. It develops a pipeline of oral nonpeptide chemical entities that target peptide G protein coupled receptors (GPCRs) for the treatment of endocrine diseases. The Company’s lead product candidate is CRN00808 developed for the treatment of acromegaly. It also develops two other product candidates CRN02481 for hyperinsulinemia, and CRN01941 for the treatment of neuroendocrine tumors. CRN02481 and CRN01941 are both oral nonpeptide somastatin receptors that are in the pre-clinical stages of development. The company also conducts research programs on developing nonpeptide products for the treatment of Cushing’s disease.

Last Annual December 31st, 2019
Last Interim March 31st, 2020
Incorporated November 18, 2008
Public Since July 18, 2018
No. of Shareholders: 19
No. of Employees: 68
Sector Healthcare
Industry Biotechnology & Medical Research
Index Nasdaq Composite ,
Exchange NASDAQ Global Select Market
Shares in Issue 32,845,572
Free Float (0.0%)
Eligible for
CRNX Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for CRNX
Upcoming Events for CRNX
Frequently Asked Questions for Crinetics Pharmaceuticals Inc
What is the Crinetics Pharmaceuticals Inc share price?

As of 7:32pm, shares in Crinetics Pharmaceuticals Inc are trading at $17.06, giving the company a market capitalisation of £465.2m. This share price information is delayed by 15 minutes.

How has the Crinetics Pharmaceuticals Inc share price performed this year?

Shares in Crinetics Pharmaceuticals Inc are currently trading at $17.06 and the price has moved by -28.3% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Crinetics Pharmaceuticals Inc price has moved by -30.71% over the past year.

What are the analyst and broker recommendations for Crinetics Pharmaceuticals Inc?

Of the analysts with advisory recommendations for Crinetics Pharmaceuticals Inc, there are there are currently 1 "buy" , 0 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Crinetics Pharmaceuticals Inc is Buy. You can view the full broker recommendation list by unlocking its StockReport.

When will Crinetics Pharmaceuticals Inc next release its financial results?

Crinetics Pharmaceuticals Inc is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-03-31
What is the Crinetics Pharmaceuticals Inc dividend yield?

Crinetics Pharmaceuticals Inc does not currently pay a dividend.

Does Crinetics Pharmaceuticals Inc pay a dividend?

Crinetics Pharmaceuticals Inc does not currently pay a dividend.

When does Crinetics Pharmaceuticals Inc next pay dividends?

Crinetics Pharmaceuticals Inc does not currently pay a dividend.

How do I buy Crinetics Pharmaceuticals Inc shares?

To buy shares in Crinetics Pharmaceuticals Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Crinetics Pharmaceuticals Inc?

Shares in Crinetics Pharmaceuticals Inc are currently trading at $17.06, giving the company a market capitalisation of £465.2m.

Where are Crinetics Pharmaceuticals Inc shares listed? Where are Crinetics Pharmaceuticals Inc shares listed?

Here are the trading details for Crinetics Pharmaceuticals Inc:

Country of listing: United States
Exchange: NSQ
Ticker Symbol: CRNX
What kind of share is Crinetics Pharmaceuticals Inc?

Based on an overall assessment of its quality, value and momentum, Crinetics Pharmaceuticals Inc is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Crinetics Pharmaceuticals Inc share price forecast 2020?

Shares in Crinetics Pharmaceuticals Inc are currently priced at $17.06. At that level they are trading at 0.108% discount to the analyst consensus target price of 0.00.

Analysts covering Crinetics Pharmaceuticals Inc currently have a consensus Earnings Per Share (EPS) forecast of -2.47 for the next financial year.

How can I tell whether the Crinetics Pharmaceuticals Inc share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Crinetics Pharmaceuticals Inc. Over the past six months, the relative strength of its shares against the market has been -27.63%. At the current price of $17.06, shares in Crinetics Pharmaceuticals Inc are trading at -5.58% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Crinetics Pharmaceuticals Inc PE Ratio?

We were not able to find PE ratio data for Crinetics Pharmaceuticals Inc.

Who are the key directors of Crinetics Pharmaceuticals Inc?

Crinetics Pharmaceuticals Inc's management team is headed by:

Wendall Wierenga - CHM
R. Scott Struthers - PRE
Ajay Madan - OTH
Marc Wilson - CFO
Alan Krasner - OTH
Matthew Fust - IND
Stephen Kaldor - IND
Weston Nichols - IND
Stephanie Okey - IND
Adriana Cabre - VPR
Who are the major shareholders of Crinetics Pharmaceuticals Inc?

Here are the top five shareholders of Crinetics Pharmaceuticals Inc based on the size of their shareholding:

Perceptive Advisors LLC Private Equity
Percentage owned: 11.14% (3.66m shares)
Fidelity Management & Research Company Investment Advisor
Percentage owned: 10.37% (3.40m shares)
Versant Ventures Venture Capital
Percentage owned: 8.17% (2.68m shares)
Vivo Capital, LLC Venture Capital
Percentage owned: 7.51% (2.47m shares)
OrbiMed Advisors, LLC Investment Advisor/Hedge Fund
Percentage owned: 6.21% (2.04m shares)
Similar to CRNX
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.